The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Merger is expected to streamline operations and provide unified management focus, driving efficiency and strategic alignment
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
Subscribe To Our Newsletter & Stay Updated
